Get the Stockscreener App
17.80
4.09%
0.70
Adma Biologics Inc stock is traded at $17.80, with a volume of 2.34M.
It is up +4.09% in the last 24 hours and up +4.40% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$17.10
Open:
$17.13
24h Volume:
2.34M
Relative Volume:
0.79
Market Cap:
$4.25B
Revenue:
$426.45M
Net Income/Loss:
$197.67M
P/E Ratio:
21.71
EPS:
0.82
Net Cash Flow:
$110.10M
1W Performance:
+4.77%
1M Performance:
+4.40%
6M Performance:
+12.37%
1Y Performance:
+1.71%
1-Day Range:
$16.99
$17.84
1-Week Range:
$16.85
$17.89
52-Week Range:
$14.62
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
17.80 | 4.21B | 426.45M | 197.67M | 110.10M | 0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
New Strong Buy Stocks for October 7th - MSN
Live Scanner Shows Breakout on ADMA Biologics Inc.2025 Pullback Review & Target Return Focused Stock Picks - kangso.co.kr
ADMA Biologics Shares Surge Amid Market Optimism - TipRanks
ADMA Biologics Inc. Added to Custom Quant Screener TodayForecast Cut & Fast Exit Strategy with Risk Control - metrotimes.co.kr
Adma Biologics CEO Adam Grossman sells $354k in shares By Investing.com - Investing.com Canada
Adma Biologics CEO Adam Grossman sells $354k in shares - Investing.com
Published on: 2025-08-15 19:06:15 - thegnnews.com
ADMA Biologics (NASDAQ:ADMA) Is Posting Healthy Earnings, But It Is Not All Good News - 富途牛牛
Why ADMA Biologics Inc. stock attracts strong analyst attentionFree Double Return Watchlist - thegnnews.com
ADMA projects $1.1B revenue before 2030 as yield enhancement drives margin expansion and ASCENIV growth - MSN
How did ADMA's revenue surge in Q4 2024 impact its profitability? - AInvest
ADMA Biologics: Optionality With SG-001 And A Vertically Integrated IG Platform - Seeking Alpha
Is ADMA Biologics Inc. forming a double bottomHigh Octane Equity Watchlist - newsyoung.net
Insider Sellers Might Regret Selling ADMA Biologics Shares at a Lower Price Than Current Market Value - 富途牛牛
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum - MSN
ADMA Biologics Thrives With Blockbuster Growth And New FDA Edge - Finimize
ADMA Biologics Earnings Call Highlights Robust Growth - The Globe and Mail
ADMA Biologics' Stock Underperforms After Q1 Results - AInvest
ADMA Biologics: A Better Quarter Than Headline Numbers (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics, Inc. (NASDAQ:ADMA) Q2 2025 Earnings Call Transcript - Insider Monkey
ADMA Biologics 2025 Q2 Earnings Strong Performance as Net Income Rises 6.7% - AInvest
ADMA Biologics Secures $300M Credit Agreement with JPMorgan - AInvest
ADMA Biologics Rides ASCENIV Demand To Higher Guidance - Finimize
ADMA Biologics Outpaces Expectations With Upbeat Growth Plans - Finimize
Noteworthy Thursday Option Activity: ADMA, SMMT, ICHR - Nasdaq
ADMA Biologics Sees Promising Gains Amid Strategic Shifts and Rising Market Trends - timothysykes.com
Plasma Derived Medicine Market to Reach USD 37.4 Billion by 2034, Growing at 8.05% CAGR - GlobeNewswire Inc.
ADMA Beats On Q2 Earnings And Revenues, Asceniv Drives Momentum - Barchart.com
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Earnings call transcript: ADMA Biologics Q2 2025 misses earnings expectations By Investing.com - Investing.com South Africa
Earnings call transcript: ADMA Biologics Q2 2025 misses earnings expectations - Investing.com
ADMA Biologics Inc earnings missed, revenue fell short of estimates By Investing.com - Investing.com UK
Adma Biologics (ADMA) Q2 Revenue Up 14% - AOL.com
ADMA Biologics Reports Strong Q2 2025 Results - TipRanks
ADMA Biologics Q2 2025 Earnings Call Transcript - MarketBeat
ADMA Biologics (ADMA) Projects Significant Growth with Yield Process and Refinancing - GuruFocus
ADMA Biologics: A Tale of Two Narratives—Strong Fundamentals vs. a Pessimistic Rating - AInvest
ADMA Biologics' Q2 2025: Unraveling Contradictions in Yield Enhancements, Reimbursement, and Demand Dynamics - AInvest
ADMA Biologics Q2 2025 Earnings Call Transcript Review - AInvest
ADMA Biologics' Q2 2025 Earnings and Strategic Outlook: Navigating Insider Sales and Risk Disclosures for Long-Term Value - AInvest
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adma Biologics Inc Stock (ADMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
Aug 15 '25 |
Sale |
16.88 |
21,000 |
354,480 |
2,031,850 |
| Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance |
Jul 30 '25 |
Option Exercise |
8.98 |
2,500 |
22,450 |
489,898 |
| Grossman Adam S | President and CEO |
Jul 15 '25 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,058,850 |
| Grossman Adam S | President and CEO |
Jul 15 '25 |
Sale |
18.66 |
21,000 |
391,860 |
2,037,850 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):